Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16766 | 0.92 | EPHX1 (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14891993 | 0.80 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14924188 | 0.76 | USP2 (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL18256712 | 0.76 | AOC2 (0.34) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL3463025 | 0.73 | EPHX1 (0.38) | EPHX1 | |
| SCHEMBL19286017 | 0.73 | EPHX1 (0.40) | EPHX1 | |
| SCHEMBL7814512 | 0.73 | KMT2A (0.39) | ALDH1A1 | |
| SCHEMBL23142449 | 0.72 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL15353749 | 0.72 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL3462689 | 0.72 | KDM4E (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124613-B2 | Spirotropane compounds | VIROCHEM PHARMA INC. (CA) | 2012-02-28 | — | — | US | disclosed |
| US-20110105546-A1 | SPIROTROPANE COMPOUNDS | VIROCHEM PHARMA INC. (CA) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105546-A1 | SPIROTROPANE COMPOUNDS | CCR5, CXCR1, CXCR2 | KDM4E 4880/4885USP2 4658/4885ALDH1A1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.